Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES F LOVELL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1174629448
CMS profile
325880
Location
NORFOLK, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$2,823.11

39 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $2,168.00 2
Food and Beverage $586.93 35
Education $56.45 1
Travel and Lodging $11.73 1

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES F LOVELL

NPI 1174629448 · CMS profile ID 325880

Allopathic & Osteopathic Physicians / Internal Medicine

NORFOLK, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174629448?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174629448?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174629448?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1174629448?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

39 matching records · $2,823.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 39 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–39 of 39.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $8.8012/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736085981 CMS
Lilly USA, LLC $11.6711/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728399275 CMS
Amarin Pharma Inc. $13.5010/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739832297 CMS
AstraZeneca Pharmaceuticals LP $21.8910/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736025485 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.2909/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720919095 CMS
Relypsa, Inc. $20.0309/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742183261 CMS
Arbor Pharmaceuticals, Inc. $11.0708/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735730701 CMS
Amarin Pharma Inc. $14.2408/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739827857 CMS
AstraZeneca Pharmaceuticals LP $22.8408/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735918897 CMS
Allergan, Inc. $17.4907/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723425119 CMS
Amarin Pharma Inc. $14.4507/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739832383 CMS
Strongbridge US INC. $13.2707/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735174719 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.2307/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720919101 CMS
Novartis Pharmaceuticals Corporation $17.6906/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725995793 CMS
Strongbridge US INC. $16.8006/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735174421 CMS
Janssen Pharmaceuticals, Inc $14.7006/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719075193 CMS
AstraZeneca Pharmaceuticals LP $512.0006/16/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736070423 CMS
AstraZeneca Pharmaceuticals LP $15.0406/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736078361 CMS
Amarin Pharma Inc. $14.5605/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739827849 CMS
AstraZeneca Pharmaceuticals LP $19.3705/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736106001 CMS
Amarin Pharma Inc. $14.5504/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739827853 CMS
Janssen Pharmaceuticals, Inc $13.6004/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719075195 CMS
Hikma Pharmaceuticals USA $13.8204/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 729269397 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $11.8404/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720919105 CMS
AstraZeneca Pharmaceuticals LP $21.1003/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735843081 CMS
Corcept Therapeutics $15.2503/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744739189 CMS
Amarin Pharma Inc. $19.4203/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739839785 CMS
Kowa Pharmaceuticals America, Inc. $11.7303/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716758575 CMS
E.R. Squibb & Sons, L.L.C. $20.2603/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727981161 CMS
E.R. Squibb & Sons, L.L.C. $11.7303/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727981165 CMS
Novartis Pharmaceuticals Corporation $19.6803/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725995791 CMS
E.R. Squibb & Sons, L.L.C. $1,656.0003/06/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727981155 CMS
Alnylam Pharmaceuticals Inc. $56.4503/02/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750758649 CMS
Hikma Pharmaceuticals USA $16.8802/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 729269395 CMS
AstraZeneca Pharmaceuticals LP $24.0202/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735895337 CMS
AstraZeneca Pharmaceuticals LP $50.4002/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736289281 CMS
Amarin Pharma Inc. $13.5001/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739839789 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $10.9901/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720919109 CMS
Novartis Pharmaceuticals Corporation $13.9601/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725995789 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,516.90 64
PY2020 $2,823.11 39
PY2021 $2,590.74 45
PY2022 $737.64 35
PY2023 $454.03 20
PY2024 $2,529.63 39
PY2025 $681.28 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $262,318.22 41
PY2024 Principal investigator $226,779.68 27
PY2023 Principal investigator $241,422.11 79
PY2022 Principal investigator $283,192.02 266
PY2021 Principal investigator $197,651.91 425
PY2020 Principal investigator $248,697.42 325
PY2019 Recipient $12,988.10 1
PY2019 Principal investigator $359,002.06 260

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

79 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,904.47 12/31/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio No dispute reported 06/30/2026 991128929
Principal investigator 1 Novo Nordisk AS $29.00 12/29/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1007778229
Principal investigator 1 ModernaTX, Inc. $151.20 12/20/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042259901
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,595.00 12/19/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
A randomized, controlled, multicenter, open-label trial comparing a post-discharge care pathway involving aggressive LDL-C management with inclisiran with usual care in patients with a recent acute coronary syndrome No dispute reported 06/30/2026 1017199493
Principal investigator 1 Novo Nordisk AS $2,783.27 12/18/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1008961153
Principal investigator 1 ModernaTX, Inc. $302.40 12/06/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042259903
Principal investigator 1 Novo Nordisk AS $29.00 11/30/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1007151115
Principal investigator 1 Novo Nordisk AS $20,661.40 11/29/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1008164641
Principal investigator 1 Novo Nordisk AS $7,000.06 11/27/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1008961135
Principal investigator 1 Novo Nordisk AS $500.00 11/03/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1008164627
Principal investigator 1 Novo Nordisk AS $29.00 10/31/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1007151103
Principal investigator 1 ModernaTX, Inc. $1,291.68 10/25/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042259883
Principal investigator 1 ModernaTX, Inc. $1,852.92 10/06/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042259881
Principal investigator 1 Novo Nordisk AS $29.00 09/29/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1007151079
Principal investigator 1 Novo Nordisk AS $1,168.02 09/25/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1008164613
Principal investigator 1 Novo Nordisk AS $1,000.00 09/22/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1008164599
Principal investigator 1 Novo Nordisk AS $1,761.20 09/22/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1008961101
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,438.31 09/15/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio No dispute reported 06/30/2026 991135079
Principal investigator 1 Novo Nordisk AS $29.00 08/31/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1007151091
Principal investigator 1 ModernaTX, Inc. $4,181.76 08/18/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042259837
Principal investigator 1 Novo Nordisk AS $5,657.04 08/18/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1008164583
Principal investigator 1 Novo Nordisk AS $673.32 08/18/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1008961085
Principal investigator 1 Novo Nordisk AS $23.06 08/18/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1008961117
Principal investigator 1 Novo Nordisk AS $3,162.50 08/04/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1008164569
Principal investigator 1 Novo Nordisk AS $29.00 07/31/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1007151067
Principal investigator 1 Novo Nordisk AS $23.06 07/27/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007796985
Principal investigator 1 Novo Nordisk AS $898.02 07/26/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1008164555
Principal investigator 1 Novo Nordisk AS $23.06 07/25/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007796993
Principal investigator 1 Novo Nordisk AS $75.00 07/18/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007796977
Principal investigator 1 ModernaTX, Inc. $1,776.60 07/12/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042259835
Principal investigator 1 Novo Nordisk AS $23.06 07/07/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007796969
Principal investigator 1 Novo Nordisk AS $2,977.14 07/03/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9924-4635 No dispute reported 06/30/2026 1008311853
Principal investigator 1 Novo Nordisk AS $23.06 07/02/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007925759
Principal investigator 1 Novo Nordisk AS $29.00 06/30/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1007151043
Principal investigator 1 Novo Nordisk AS $9.99 06/30/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007822209
Principal investigator 1 Novo Nordisk AS $218.30 06/30/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007822215
Principal investigator 1 Novo Nordisk AS $7.49 06/30/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007925783
Principal investigator 1 Novo Nordisk AS $709.31 06/23/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007822229
Principal investigator 1 Novo Nordisk AS $23.06 06/16/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007925771
Principal investigator 1 Novo Nordisk AS $46.12 06/13/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007925777
Principal investigator 1 ModernaTX, Inc. $6,106.26 06/07/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042259833
Principal investigator 1 Novo Nordisk AS $29.00 05/31/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1007151055
Principal investigator 1 Novo Nordisk AS $709.31 05/26/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007822223
Principal investigator 1 Novo Nordisk AS $10,472.76 05/26/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1008164541
Principal investigator 1 Novo Nordisk AS $20.10 05/12/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1006778161
Principal investigator 1 ModernaTX, Inc. $3,611.58 05/03/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042259815
Principal investigator 1 Novo Nordisk AS $29.00 04/28/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1007151029
Principal investigator 1 Novo Nordisk AS $1,917.02 04/26/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007797003
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,069.40 04/25/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
A randomized, controlled, multicenter, open-label trial comparing a post-discharge care pathway involving aggressive LDL-C management with inclisiran with usual care in patients with a recent acute coronary syndrome No dispute reported 06/30/2026 1017199681
Principal investigator 1 Novo Nordisk AS $1,797.84 04/24/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1006778173
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,006.58 03/31/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1017199241
Principal investigator 1 Novo Nordisk AS $29.00 03/31/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1007132631
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,846.81 03/30/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension No dispute reported 06/30/2026 1017199003
Principal investigator 1 ModernaTX, Inc. $3,094.20 03/29/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042259813
Principal investigator 1 Novo Nordisk AS $5,129.46 03/24/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1006778149
Principal investigator 1 Novo Nordisk AS $414.57 03/24/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007925745
Principal investigator 1 Novo Nordisk AS $41.26 03/02/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9924-4635 No dispute reported 06/30/2026 1007238701
Principal investigator 1 Novo Nordisk AS $29.00 02/28/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1007132615
Principal investigator 1 Novo Nordisk AS $70.00 02/28/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9924-4635 No dispute reported 06/30/2026 1008311839
Principal investigator 1 ModernaTX, Inc. $2,770.20 02/24/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042259811
Principal investigator 1 Novo Nordisk AS $772.92 02/24/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9924-4635 No dispute reported 06/30/2026 1007238689
Principal investigator 1 Novo Nordisk AS $1,404.54 02/22/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1006778137
Principal investigator 1 Novo Nordisk AS $1,027.97 02/22/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007925739
Principal investigator 1 Novo Nordisk AS $23.06 02/17/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007925765
Principal investigator 1 Novo Nordisk AS $29.00 01/31/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1007132597
Principal investigator 1 Novo Nordisk AS $70.00 01/31/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9924-4635 No dispute reported 06/30/2026 1007238711
Principal investigator 1 Novo Nordisk AS $79.92 01/30/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007925733
Principal investigator 1 ModernaTX, Inc. $2,142.72 01/27/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042259809
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $31,590.01 01/27/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 1006165685
Principal investigator 1 Novartis Pharmaceuticals Corporation $37,615.13 01/26/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1017198949
Principal investigator 1 Novo Nordisk AS $23.06 01/26/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1008258851
Principal investigator 1 Novo Nordisk AS $5,036.04 01/25/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1006778123
Principal investigator 1 Novo Nordisk AS $2,602.40 01/25/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007925751
Principal investigator 1 Novo Nordisk AS $2,275.20 01/25/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9924-4635 No dispute reported 06/30/2026 1008311825
Principal investigator 1 Novo Nordisk AS $23.06 01/24/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1008258865
Principal investigator 1 Novo Nordisk AS $11.64 01/23/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1006778111
Principal investigator 1 Amgen Inc. $771.00 01/21/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
P0 ASCVD Olpasiran Prescreening for CVOT No dispute reported 06/30/2026 1029651463
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,564.15 01/15/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1017199555
Principal investigator 1 Novo Nordisk AS $23.06 01/06/2023 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4321 No dispute reported 06/30/2026 1007925727